PPARGC1A and amyotrophic lateral sclerosis: Given PGC‐1α's reduced expression in ALS patient muscle tissue [114], its activation demonstrates therapeutic potential by enhancing mitochondrial biogenesis (improved respiratory chain complex activity), reducing ROS toxicity (decreased superoxide levels), and modulating neuromuscular junction gene expression [115, 116].